Answers are grounded in this paper and cite their sources.
OBJECTIVES/BACKGROUND: This study was undertaken to summarize the baseline methods for the Headache Assessment via Digital Platform in United States (HeAD-US) study and report accuracy of self-reported diagnosis of migraine on the platform and patterns of acute and preventive treatment use among participants with migraine. HeAD-US is a new, ongoing cohort study of patients with migraine in the United States, centered around comprehensive data collection via the Migraine Buddy platform, a smartphone app. Data from such platforms can be used to provide real-world insights, capturing patients' voices directly. METHODS: Participants from the app completed baseline surveys for approximately 3 months starting in September 2023, assessing demographics, headache characteristics, and treatment use. Migraine diagnosis was determined using the American Migraine Study/American Migraine Prevalence and Prevention diagnostic module, and treatment effectiveness was evaluated using the migraine Treatment Optimization Questionnaire-6 (defined as scores ≥ 6 indicating moderate-to-maximum effectiveness). RESULTS: Of 6810 participants who completed the baseline questionnaire, 6267 (92.0%) met migraine criteria and were included in the rest of the study. Participants had an average age of 41.5 years (SD = 13.1, range = 18-88), 5692 (90.8%) were female, 3924 (62.6%) met criteria for episodic migraine, and 2343 (37.4%) met criteria for chronic migraine. Of the participants, 52.6% were using acute over-the-counter (OTC) medications, 73.7% were using acute prescription medications, 2.4% were using medical devices, and 60.1% were on preventive treatments. There was no significant difference in treatment effectiveness between participants on polytherapy (37.6%) and those on monotherapy (39.5%, p = 0.168). Among the 2421 patients on monotherapy with acute medications, the most common categories were triptans (42.2%), over-the-counter medications (30.5%), and gepants (23.8%). For patients on prescription monotherapy, individuals using gepants reported the highest rate of effective treatment (53.3%) in head-to-head comparison with triptans (47.8%, p = 0.036) and opioid/barbiturates (27.1%, p < 0.001). CONCLUSION: HeAD-US participants have higher rates of chronic migraine and headache-related disability in comparison with large-scale epidemiologic studies. The HeAD-US study offers a valuable opportunity to leverage real-world data for understanding patients with migraine, their treatment patterns, and outcomes.
No takes yet. Share an insight, caveat, or question.
Ezzati et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: